Rigel drops asthma drug after trial fails, stock hits life-low – Reuters


The Denver Channel

Rigel drops asthma drug after trial fails, stock hits life-low
Reuters
(Reuters) – Rigel Pharmaceuticals Inc said it will stop developing its experimental asthma drug after the therapy failed in a mid-stage trial, sending its shares down as much as 17 percent to a life-low. The failure of the inhaled drug is the latest
Rigel Shares Plunge After Asthma Drug Fails to Meet GoalsBloomberg
Rigel shares slide after another drug flops in PhII asthma studyFierceBiotech
Rigel Pharmaceuticals skids after asthma drug fails in studyThe Denver Channel
Wall Street Journal –PR Newswire (press release) –NASDAQ
all 30 news articles »

View full post on asthma – Google News